KALA BIO, Inc.
KALAKALA BIO is a biopharmaceutical company in transition, pivoting from traditional drug development to the creation of a specialized artificial intelligence infrastructure platform for the biotechnology and pharmaceutical industries.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
KALA BIO is a biopharmaceutical company in transition, pivoting from traditional drug development to the creation of a specialized artificial intelligence infrastructure platform for the biotechnology and pharmaceutical industries. The company leverages its proprietary biological datasets and research experience to develop secure, on-premises AI systems that allow clients to analyze sensitive research data without compromising intellectual property or regulatory compliance. Its core value proposition centers on providing 'agentic' AI that can autonomously manage complex research workflows, such as clinical trial analysis and literature synthesis, within a private enterprise environment.
A transitioning clinical-stage biotech company attempting to carve out a niche in private, secure AI infrastructure for highly regulated life sciences data.
Questions, answered.
- What is KALA BIO, Inc.'s market cap?
- KALA BIO, Inc. (KALA) has a market capitalization of $12.5M and trades on NASDAQ.
- Who are KALA BIO, Inc.'s competitors?
- KALA BIO, Inc.'s key competitors include Microsoft, Alphabet Inc., Schrödinger, Inc., and others. These companies compete in similar markets and product categories.
- Who does KALA BIO, Inc. partner with?
- KALA BIO, Inc.'s notable partners include Younet AI, AK Holdings Group Inc..
- What subsidiaries does KALA BIO, Inc. have?
- KALA BIO, Inc.'s subsidiaries include Combangio, Inc..
- Where is KALA BIO, Inc. headquartered?
- KALA BIO, Inc. is headquartered in United States of America and employs approximately 43 people. It has been publicly traded since 2017.